RESUMO
Mostra como a história da vacina contra a febre amarela é uma história que deságua em pontas inacabadas: iniciou-se, do ponto de vista institucional, com a Fundação Rockefeller, teve sua continuidade garantida pelo Instituto Oswaldo Cruz, e foi herdada por Bio-Manguinhos que se empenha para assegurar a transmissão desse legado.
Assuntos
Febre Amarela/prevenção & controle , Vacina contra Febre Amarela/história , Brasil , Cooperação Internacional , Saúde Pública/históriaRESUMO
The use of yellow fever (YF) virus 17D strain for vaccine production adapted in Brazil since its introduction in 1937 was reviewed. This was possible due to the availability of official records of vaccine production. The retrieved data highlight the simultaneous use of several serially passaged 17D substrain viruses for both inocula and vaccine preparation that allowed uninterrupted production. Substitution of these substrain viruses became possible with the experience gained during quality control and human vaccination. Post-vaccinal complications in humans and the failure of some viruses in quality control tests (neurovirulence for monkeys) indicated that variables needed to be reduced during vaccine production, leading to the development of the seed lot system. The 17DD substrain, still used today, was the most frequently used substrain and the most reliable in terms of safety and efficacy. For this reason, it is possible to derive an infectious cDNA clone of this substrain combined with production in cell culture that could be used to direct the expression of heterologous antigens and lead to the development of new live vaccines